The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Boehringer Ingelheim's all oral Hepatitis C drugs cured 82 percent of patients with the most common type of Hepatitis C in mid-stage trials. In addition, these drugs exhibited the potential to cure people with cirrhosis.
Continue reading »Quercetin is a relative newcomer to the arsenal of nutritional supplements believed to help those with Hepatitis C.
Continue reading »SST (Sho-saiko-to) is made up of seven medicinal plants which, when used together, help to build immunity and stabilize liver health. Learn more about the benefits of SST, and why it was temporarily unavailable until just recently.
Continue reading »A combination of oral drugs - ribavirin and two of Abbott's drugs in development - demonstrated unprecedented Hepatitis C cure rates in a small, mid-stage study.
Continue reading »Using an approach called exhaustive panning, Scripps researchers have advanced the search for a Hepatitis C vaccine by identifying the antibody AR4A.
Continue reading »The stigma surrounding addiction may discourage Hepatitis C treatment for drug users - but the evidence encourages these individuals to do triple therapy.
Continue reading »The individual who first identified the Hepatitis C virus might be the same person responsible for ending its infectious reign.
Continue reading »By delivering genetic material to initiate a T cell response, Okairos is looking to create the first Hepatitis C preventative vaccine.
Continue reading »Boasting the world's highest rate of Hepatitis C, Egypt has a lot to gain from the American University in Cairo's fast and inexpensive Hepatitis C test.
Continue reading »In two separate Phase 3 trials, Hepatitis C patients with genotypes 1 and 4 are being treated with TMC435 plus pegylated interferon and ribavirin.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
